Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab.
Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab.
Br J Dermatol. 2020 Apr 22;:
Authors: Harrer A, Lang R, Kölblinger P
Abstract
We read with interest the BJD online publication by Gambichler and colleagues1 about a decline of programmed death (PD)-1+ circulating T regulatory cells (Tregs) predicting clinical outcome in anti-PD-1 therapy. The study highlights the potential and importance of immune monitoring in anti-PD-1 checkpoint therapy in malignant melanoma. However, their conclusion about anti-PD-1 antibody treatment effecting a decline of PD-1+ Tregs is misleading.
PMID: 32319671 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Harrer A, Lang R, Kölblinger P Tags: Br J Dermatol Source Type: research
More News: Cancer & Oncology | Dermatology | Lessons | Melanoma | Skin | Skin Cancer | Study | Tysabri | UK Health